



GENITOURINARY TUMORS CONCLAVE 2022

BEYOND THE GUIDELINES:
CLINICAL PERSPECTIVES
ON THE MANAGEMENT OF
GENITOURINARY TUMORS

SAVE THE DATE

8th – 9th July, 2022

6:30 – 9:10 pm

Program Directors



Dr. Hemant Malhotra

Director, Oncology Services,
Sri Ram Cancer & Super Speciality Center &
Prof. & Head, Dept. of Medical Oncology,
Mahatma Gandhi Medical College Hospital,
Jaipur



Dr. Sadashivudu Gundeti

Additional Professor & HOD,
Nizam's Institute of Medical Sciences,
Hyderabad

[Click here for disclaimer](#)

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory



Pfizer Products India Private Limited ("Pfizer") The Capital, B wing, 1802, Plot No. C-70, G Block,
Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India

This email message is intended for registered Healthcare Practitioner (HCP)

Disclaimer- Kindly note that the article provided is procured only for the use of the requestor, to keep them updated on recent medical developments and advances. This article is for your personal reference. Per copyright policy, it is not to be further reproduced or disseminated.
Legal Notice - Unless expressly stated otherwise, this message is confidential and may be privileged. It is intended for the addressee[s] only. Access to this e-mail by anyone else is unauthorized. If you are not an addressee, any disclosure or copying of the contents of this e-mail or any action taken [or not taken] in reliance on it is unauthorized and may be unlawful. If you are not an addressee, please inform the sender immediately



GENITOURINARY TUMORS CONCLAVE 2022

BEYOND THE GUIDELINES:
CLINICAL PERSPECTIVES ON
THE MANAGEMENT
OF GENITOURINARY TUMORS

8th – 9th July, 2022

8th July 2022 | 6:30–9:10 pm

Day 1

Scientific Program

6:30 – 6:40 pm	Welcome and Introduction Program Director & Pfizer Medical
6:40 – 7:00 pm	Current Treatment landscape for first line therapy for urothelial carcinoma Speaker : Dr. Meenu Walia
7:00 – 7:30 pm	Challenges in selecting first-line therapy for urothelial carcinoma – <ul style="list-style-type: none">• Current first-line therapy guidelines and recommendations• Clinical scenarios in which ICI therapy is the optimal treatment course<ul style="list-style-type: none">• Cisplatin-ineligible patients• PD-L1 expression and agent specific assays and expression thresholds Speaker : Dr. Thomas Powles
7:30 – 7:50 pm	Treatment Refractory advanced urothelial cancer <ul style="list-style-type: none">• Sequencing strategies, considerations, and challenges Speaker : Dr. B J Srinivas
7:50 – 8:10 pm	Key studies in urothelial carcinoma– Conference highlights from ASCO GU 2022 and ASCO Speaker : Dr. Chirag Desai

[Click here for disclaimer](#)

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory



Pfizer Products India Private Limited ("Pfizer") The Capital, B wing, 1802, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India

This email message is intended for registered Healthcare Practitioner (HCP)

Disclaimer- Kindly note that the article provided is procured only for the use of the requestor, to keep them updated on recent medical developments and advances. This article is for your personal reference. Per copyright policy, it is not to be further reproduced or disseminated.
Legal Notice - Unless expressly stated otherwise, this message is confidential and may be privileged. It is intended for the addressee[s] only. Access to this e-mail by anyone else is unauthorized. If you are not an addressee, any disclosure or copying of the contents of this e-mail or any action taken [or not taken] in reliance on it is unauthorized and may be unlawful. If you are not an addressee, please inform the sender immediately



GENITOURINARY TUMORS CONCLAVE 2022

BEYOND THE GUIDELINES:
CLINICAL PERSPECTIVES ON
THE MANAGEMENT
OF GENITOURINARY TUMORS

8th – 9th July, 2022

8th July 2022 | 6:30–9:10 pm

Day 1

Scientific Program

8:10 – 8:25 pm

Case presentation- An Indian Perspective
Critical analysis of the case
Speaker : Dr. P S Dattatreya

8:25 – 8:40 pm

Panel Discussion: Considerations related to
everyday clinical practice
Moderator : Dr. Vineet Talwar
Panelists : All speakers

8:40 – 9:00 pm

Chairperson : Dr. Rajat Saha

Debate:
What is the best strategy for management of
cisplatin ineligible patients: Gem-carbo
followed by IO maintenance or IO
monotherapy
For : Dr. Biwas Biswas
Against : Dr. Priya Tiwari

9:00 – 9:05 pm

Live Q and A

9:05 – 9:10 pm

Closing Remarks
Program Director & Pfizer Medical

[Click here for disclaimer](#)



Pfizer Products India Private Limited ("Pfizer") The Capital, B wing, 1802, Plot No. C-70, G Block,
Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India

This email message is intended for registered Healthcare Practitioner (HCP)

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory

Disclaimer- Kindly note that the article provided is procured only for the use of the requestor, to keep them updated on recent medical developments and advances. This article is for your personal reference. Per copyright policy, it is not to be further reproduced or disseminated.
Legal Notice - Unless expressly stated otherwise, this message is confidential and may be privileged. It is intended for the addressee[s] only. Access to this e-mail by anyone else is unauthorized. If you are not an addressee, any disclosure or copying of the contents of this e-mail or any action taken [or not taken] in reliance on it is unauthorized and may be unlawful. If you are not an addressee, please inform the sender immediately



GENITOURINARY TUMORS CONCLAVE 2022

BEYOND THE GUIDELINES:
CLINICAL PERSPECTIVES ON
THE MANAGEMENT
OF GENITOURINARY TUMORS

8th – 9th July, 2022

9th July 2022 | 6:30–9:10 pm

Day 2

Scientific Program

6:30 – 6:40 pm	Welcome and Introduction Program Director & Pfizer Medical
6:40 – 7:00 pm	Current Treatment landscape for first line therapy for renal cell carcinoma Speaker : Dr. Mohit Agarwal
7:00 – 7:30 pm	Immuno-Oncology combinations in Advanced RCC: Building on recent progress and improving patient outcomes Speaker : Dr. Enrique Grande
7:30 – 7:50 pm	Treatment Refractory advanced renal cell carcinoma-Second line therapy and beyond <ul style="list-style-type: none">• Sequencing strategies, considerations, and challenges Speaker : Dr. Amit Joshi
7:50 – 8:10 pm	Key studies in metastatic renal carcinoma-Conference highlights from ASCO GU 2022 and ASCO Speaker : Dr. Vindhya Vasini
8:10 – 8:25 pm	Case presentation- An Indian Perspective Critical analysis of the case Speaker : Dr. P N Mohapatra
8:25 – 8:40 pm	Panel Discussion : Considerations related to everyday clinical practice and discussion Moderator : Dr. Prasad Narayanan Panelists : All speakers

[Click here for disclaimer](#)



Pfizer Products India Private Limited ("Pfizer") The Capital, B wing, 1802, Plot No. C-70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India

This email message is intended for registered Healthcare Practitioner (HCP)

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory

Disclaimer- Kindly note that the article provided is procured only for the use of the requestor, to keep them updated on recent medical developments and advances. This article is for your personal reference. Per copyright policy, it is not to be further reproduced or disseminated.
Legal Notice - Unless expressly stated otherwise, this message is confidential and may be privileged. It is intended for the addressee[s] only. Access to this e-mail by anyone else is unauthorized. If you are not an addressee, any disclosure or copying of the contents of this e-mail or any action taken [or not taken] in reliance on it is unauthorized and may be unlawful. If you are not an addressee, please inform the sender immediately



GENITOURINARY TUMORS CONCLAVE 2022

BEYOND THE GUIDELINES:
CLINICAL PERSPECTIVES ON
THE MANAGEMENT
OF GENITOURINARY TUMORS

8th – 9th July, 2022

9th July 2022 | 6:30–9:10 pm

Day 2

Scientific Program

8:40 – 9:00 pm

Chairperson : Dr. Kumar Prabhash

Debate:

Immune Checkpoint Inhibitor Combination
Therapy versus TKI alone as First-Line
Treatment for Favorable-IMDC-Risk Advanced
Renal Cell Carcinoma Patients

For : Dr. Ashish Singh

Against : Dr. Ravi Thippeswamy

9:00 – 9:05 pm

Live Q and A

9:05 – 9:10 pm

Closing Remarks

Program Director & Pfizer Medical

Webinar Management

riveroute[®]

Leaders in Streaming Modules

Mobile: +91 9082484474

E-mail : rrcg.pravin@gmail.com

[Click here for disclaimer](#)



Pfizer Products India Private Limited ("Pfizer") The Capital, B wing, 1802, Plot No. C-70, G Block,
Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India

This email message is intended for registered Healthcare Practitioner (HCP)

Disclaimer- Kindly note that the article provided is procured only for the use of the requestor, to keep them updated on recent medical developments and advances. This article is for your personal reference. Per copyright policy, it is not to be further reproduced or disseminated.
Legal Notice - Unless expressly stated otherwise, this message is confidential and may be privileged. It is intended for the addressee[s] only. Access to this e-mail by anyone else is unauthorized. If you are not an addressee, any disclosure or copying of the contents of this e-mail or any action taken [or not taken] in reliance on it is unauthorized and may be unlawful. If you are not an addressee, please inform the sender immediately